NCT03994913 - Clinical Trial to Evaluate CD19 CAR T (CT032) in Patients With Relapsed and/or Refractory Non-Hodgkin's B Cell Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 14, 2019

Primary Completion Date

January 20, 2021

Study Completion Date

May 27, 2021

Conditions

Refractory B-Cell Non-Hodgkin LymphomaRelapsed B-cell Non-Hodgkin Lymphoma

Interventions

BIOLOGICAL

CAR-CD19 T Cells

"The CAR- CD19 T cells (study drug) used in this study are chimeric antigen receptor specifically expressing T cells targeting CD19.~Fludarabine and Cyclophosphamide are used for lymphodepletion."

Trial Locations (2)

200127

Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai

310003

First Affiliated Hospital of Zhejiang University, Hangzhou